Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study

Epidemiological Features and Clinical Course of SARS-CoV-2 Infection in Cancer Patients Within the Veneto Oncology Network: the ROVID Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04811781

Enrollment

761

Registered

2021-03-23

Start date

2020-06-04

Completion date

2021-06-04

Last updated

2023-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor, Adult

Brief summary

The study aims to retrospectively collect epidemiological and clinical data in patients with solid tumors and SARS Covid2 infections belonging to oncology centers within the Veneto Oncology Network

Detailed description

The aim of this study is to create a Veneto Oncology Network with the aim of collecting clinical and epidemiological data of cancer Patients affected by SAR- Covid-2 infection over a period of 1 year. Descriptive statistical approaches will be used to process the data. The aim is to evaluate the development rate of severe clinical forms of infection in patients with SARS-Cov-2 and the possible association with tumour characteristics and treatment. In addition, the results of serological tests can be compared with the outcome of the diagnostic swabs and the clinical evolution of the infection in order to obtain more information regarding the significance of specific antibody development.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* be 18 Years and older * cancer patients belonging to Veneto 's Oncological Network * Patients with SAR COV-2 infection

Exclusion criteria

* Patients with no SAR COV2 Infection * Volunteers * No Cancer Patients

Design outcomes

Primary

Measure	Time frame
The rate of SAR-COV2 infection development in association with tumor characteristics.	through study completion, an average of 18 months.

Countries

Italy

Outcome results